Where does Respicardia, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Respicardia, Inc. ranks #20,320 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Respicardia, Inc. hold?

Respicardia, Inc. holds 14 US utility patents granted between 2015 and 2020, spanning 3 technology areas.

What is Respicardia, Inc.'s Innovation Score?

Respicardia, Inc. has an Innovation Score of 24.6 out of 100 (15th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Respicardia, Inc. focus on?

Respicardia, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 14 patents, ranking #259 of 1,943 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Respicardia, Inc.'s patent grant rate increasing or decreasing?

Respicardia, Inc.'s recent grant velocity is -73% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Respicardia, Inc.'s patents?

Respicardia, Inc.'s patents average 15.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Respicardia, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Respicardia, Inc.

USPTO PatentsView assignee record - 14 granted patents across 3 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Respicardia ranks #20,320 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 3 technology areas.

#20,320
of 49,997 US assignees by volume: 15th percentile
by Innovation Score (24.6/100): 15.3
avg claims per patent: -73%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R20320 · US Corporation #20,320 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #20,320/49,997
PHOTO-FINISH Renu Therapy
CPC-NARROW A61N · 3 areas
INNOV-THIN 24.6/100
CLAIMS-RICH 15.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -73% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Renu Therapy, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Respicardia’s 24.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (38%) Velocity 0.0 pts (0%) Breadth 6.1 pts (25%) Claim depth 9.2 pts (37%)

Qualcomm Incorporated · highest

85
Respicardia · this assignee

25
3D Lighting… · lowest

7

What this shows Respicardia's Innovation Score is 24.6/100 (15th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Respicardia?

Each dot is one of Respicardia’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Respicardia’s own 15.3 claims/patent is ABOVE the 11.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Respicardia vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Respicardia's grants concentrate

Respicardia, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2015. By volume, Respicardia sits between Renu Therapy, LLC and Revo Brand Group, LLC.

Renu Therapy

14
Resense

14
Resnent

14
Resonance Technol…

14
Retrieve Medical

14
Reveragen Biophar…

14
Revision Military

14
Revo Brand Group

14
Respicardia ◀

14

What this shows Respicardia holds 14 patents at rank #20,333, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Respicardia

By rank, the assignees closest to #20,333 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Respicardia's primary technology class.

Respicardia's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 15th percentile higher than 15% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Respicardia, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	7.1%
2016	2	14.3%
2017	2	14.3%
2018	2	14.3%
2019	4	28.6%
2020	3	21.4%

Which technologies does Respicardia, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 14

A61B - DIAGNOSIS; SURGERY; Identification 5

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Respicardia, Inc.'s patent record in context - here's where to go next.

Respicardia, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #20,320 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Respicardia, Inc. against Renu Therapy, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 24.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.